EP3755319A4 - Compounds and compositions for the treatment of muscular disorders - Google Patents

Compounds and compositions for the treatment of muscular disorders Download PDF

Info

Publication number
EP3755319A4
EP3755319A4 EP19756654.0A EP19756654A EP3755319A4 EP 3755319 A4 EP3755319 A4 EP 3755319A4 EP 19756654 A EP19756654 A EP 19756654A EP 3755319 A4 EP3755319 A4 EP 3755319A4
Authority
EP
European Patent Office
Prior art keywords
compositions
compounds
treatment
muscular disorders
muscular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19756654.0A
Other languages
German (de)
French (fr)
Other versions
EP3755319A1 (en
Inventor
George F. Schreiner
Guillermo Ceballos
Sundeep Dugar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epirium Bio Inc
Original Assignee
Epirium Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/900,533 external-priority patent/US20180193306A1/en
Application filed by Epirium Bio Inc filed Critical Epirium Bio Inc
Publication of EP3755319A1 publication Critical patent/EP3755319A1/en
Publication of EP3755319A4 publication Critical patent/EP3755319A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
EP19756654.0A 2018-02-20 2019-02-20 Compounds and compositions for the treatment of muscular disorders Withdrawn EP3755319A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/900,533 US20180193306A1 (en) 2012-03-23 2018-02-20 Compounds and compositions for the treatment of muscular disorders and bone disorders
PCT/US2019/018730 WO2019164914A1 (en) 2018-02-20 2019-02-20 Compounds and compositions for the treatment of muscular disorders

Publications (2)

Publication Number Publication Date
EP3755319A1 EP3755319A1 (en) 2020-12-30
EP3755319A4 true EP3755319A4 (en) 2021-12-01

Family

ID=67687368

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19756654.0A Withdrawn EP3755319A4 (en) 2018-02-20 2019-02-20 Compounds and compositions for the treatment of muscular disorders

Country Status (8)

Country Link
EP (1) EP3755319A4 (en)
JP (1) JP2021514380A (en)
CN (1) CN111989098A (en)
AU (1) AU2019224003A1 (en)
BR (1) BR112020016923A2 (en)
CA (1) CA3091892A1 (en)
IL (1) IL276786A (en)
WO (1) WO2019164914A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2718277A4 (en) 2011-06-06 2015-02-11 Cardero Therapeutics Inc Methods and compositions for treatment of mitochondrial toxicity
WO2017221269A1 (en) 2016-06-21 2017-12-28 Sphaera Pharma Pvt. Ltd., Utility of (+) epicatechin and their analogs
US11918570B2 (en) 2020-04-13 2024-03-05 The Research Foundation For The State University Of New York Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition
WO2024036225A1 (en) * 2022-08-10 2024-02-15 Epirium Bio Inc. Epicatechin for inhibiting glutamate toxicity

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180306A1 (en) * 2002-02-21 2003-09-25 Wyeth Follistatin domain containing proteins
JP2004161669A (en) * 2002-11-13 2004-06-10 Ito En Ltd Osteogenic promoter
CN100361655C (en) * 2005-09-05 2008-01-16 中山大学 (-)-epigallocatechin gallate-calcium complex solid dispersion and its prepn and application
WO2010067953A2 (en) * 2008-12-12 2010-06-17 가톨릭대학교 산학협력단 Pharmaceutical composition for preventing or treating osteoporosis, containing vitis vinifera seed extracts
US20180000908A1 (en) * 2008-05-14 2018-01-04 Agriculture Victoria Services Pty Ltd Methods of Treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009013766A (en) * 2007-06-20 2010-02-01 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases.
JP2010095474A (en) * 2008-10-17 2010-04-30 Ito En Ltd Calcium absorption-promoting composition and calcium absorption-promoting food and drink
JP2011006355A (en) * 2009-06-25 2011-01-13 Ito En Ltd Composition and food and drink for improving bone density
JP2013051920A (en) * 2011-09-05 2013-03-21 Ishikawa Prefectural Public Univ Corp Bone density improving supplement
EP2827856A4 (en) * 2012-03-23 2016-03-09 Cardero Therapeutics Inc Compounds and compositions for the treatment of muscular disorders
WO2014055905A1 (en) * 2012-10-04 2014-04-10 Abbott Laboratories Methods for enhancing the effect of egcg on mitigating skeletal muscle loss
MY176583A (en) * 2014-06-16 2020-08-17 Unigen Inc Compositions and methods for managing or improving bone disorders, cartilage disorders, or both

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180306A1 (en) * 2002-02-21 2003-09-25 Wyeth Follistatin domain containing proteins
JP2004161669A (en) * 2002-11-13 2004-06-10 Ito En Ltd Osteogenic promoter
CN100361655C (en) * 2005-09-05 2008-01-16 中山大学 (-)-epigallocatechin gallate-calcium complex solid dispersion and its prepn and application
US20180000908A1 (en) * 2008-05-14 2018-01-04 Agriculture Victoria Services Pty Ltd Methods of Treatment
WO2010067953A2 (en) * 2008-12-12 2010-06-17 가톨릭대학교 산학협력단 Pharmaceutical composition for preventing or treating osteoporosis, containing vitis vinifera seed extracts

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Spinal muscular atrophy - disease mechanism and therapy", 1 January 2017, ACADEMIC PRESS, article CHARLOTTE J. SUMNER ET AL: "Spinal muscular atrophy - disease mechanism and therapy /PASSAGE/", pages: 2PP, 6, 15-19, 351 - 356, XP055808563 *
CHENYU CHU ET AL: "Green Tea Extracts Epigallocatechin-3-gallate for Different Treatments", BIOMED RESEARCH INTERNATIONAL, vol. 2017, no. ID5615647, 1 January 2017 (2017-01-01), pages 1 - 9, XP055632978, ISSN: 2314-6133, DOI: 10.1155/2017/5615647 *
See also references of WO2019164914A1 *
USMANI AFREEN ET AL: "An Amazing Herb with Extraordinary Payback: Camellia sinensis STUDY ON FLOURIDE TOXICITY ON CARDIOVASCULAR SYSTEM AND INTERVENTION BY MAGNESIUM AND SELENIUM View project", 1 January 2016 (2016-01-01), XP055853951, Retrieved from the Internet <URL:https://www.researchgate.net/publication/308522406_An_Amazing_Herb_with_Extraordinary_Payback_Camellia_sinensis> [retrieved on 20211022] *

Also Published As

Publication number Publication date
EP3755319A1 (en) 2020-12-30
JP2021514380A (en) 2021-06-10
CA3091892A1 (en) 2019-08-29
CN111989098A (en) 2020-11-24
BR112020016923A2 (en) 2020-12-15
IL276786A (en) 2020-10-29
WO2019164914A1 (en) 2019-08-29
AU2019224003A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
EP3675882A4 (en) Methods and compositions for treatment of microbiome-associated disorders
EP3490603A4 (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EP3890748A4 (en) Compositions and methods for the treatment of liver disorders
EP3621973A4 (en) Compounds for the prevention and treatment of diseases and the use thereof
EP3934652A4 (en) Compounds, compositions, and methods for the treatment of disease
EP3790563A4 (en) Compositions for the treatment of skin conditions
EP3784260A4 (en) Compositions for the treatment of skin conditions
EP3755319A4 (en) Compounds and compositions for the treatment of muscular disorders
EP3352749A4 (en) Compounds and compositions for the treatment of ocular disorders
EP3906043A4 (en) Methods and compositions for the treatment of fabry disease
EP3761970A4 (en) Compositions and methods for the treatment of neurological diseases
EP3955937A4 (en) Compounds and methods for the treatment of ocular disorders
EP3810777A4 (en) Compositions and methods for the treatment and prevention of neurological disorders
EP3955926A4 (en) Compounds and methods for the treatment of ocular disorders
IL287796A (en) Compositions and methods for the treatment of atpase-mediated diseases
IL270927B (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
EP3873444A4 (en) Therapeutic compounds and compositions
EP3813872A4 (en) Compositions for the treatment of skin conditions
EP3661502A4 (en) Compounds for the prevention and treatment of medical disorders and uses thereof
EP3600324A4 (en) Drugs and compositions for the treatment of ocular disorders
EP4010347A4 (en) Compositions and methods for the treatment of pain and dependance disorders
EP3877383A4 (en) Compounds and compositions for the treatment of respiratory diseases
EP3856147A4 (en) Methods and probiotic compositions for the treatment of bone disorders
EP3820477A4 (en) Compounds, compositions, and methods for the treatment of disease
EP3873446A4 (en) Therapeutic compounds and compositions

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200915

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20211103

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/00 20060101ALI20211027BHEP

Ipc: A61K 33/06 20060101ALI20211027BHEP

Ipc: A61K 31/593 20060101ALI20211027BHEP

Ipc: C07D 311/74 20060101ALI20211027BHEP

Ipc: C07D 311/62 20060101ALI20211027BHEP

Ipc: A61P 19/10 20060101ALI20211027BHEP

Ipc: A61P 19/08 20060101ALI20211027BHEP

Ipc: A61K 31/353 20060101AFI20211027BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220604